The Vonlanthen Group is pleased to invite you to the Antibody Drug Conjugates Summit scheduled to take place on February 25-26, 2016 in Vienna, Austria.

This innovative B2B event will enable the participants to learn about protein modeling development and engineering advances, preclinical and clinical improvements, current ADC linker chemistry- better linker design for future generations, improving preclinical and clinical translation and creating strong and scalable processes.

Key Practical Learning Points of the Summit:

• Increase benefits of ADC- dial in potency, target stratified patient populations and optimize dosing regimens
• Ensure product and process robustness
• Make more evidence-based decisions
• Explore alternative opportunities for ADCs by reviewing the potential of using ADCs outside oncology
• Learn about advances in Protein Modeling and Engineering Breakthroughs
• How to screen for optimal site of conjugation, select better quality targets and explore new payload mechanisms of action?
• Linker Design Decisions, Novel Payloads and Linker Technology, Next-Generation Chemistry for Improved Conjugation and Linker Stability
• Characterization of ADCs, Preclinical and Clinical Advances, Translational Considerations
• Engineering ADCs for Developability, Enhanced Specificity and Binding, and Reduced Toxicity

Who Should Attend:
CEOs, Directors, Heads & Managers Of Leading Application Creators & Suppliers Including:

• Toxicology
• Biologics
• Molecular Biology
• Chief Technology Officer; Chief Development Officer; Chief Scientific Officer; Senior Research Officer
• Biotherapeutics; Molecular Medicine; Data analysis; Analytical & Formulation
• Oncology Drug Development; Oncology Molecules
• Medical information
• Bioanalytical
• Discovery Chemistry; Research & Development; Antibody Discovery
• Protein Engineering; Process Sciences
• Biopharmaceutical Development; Development Analytics and New Technologies:
• Clinical Assay; Biologics Discovery and Design

It is also designed for professionals who work for the Industry of:

• Pharmaceuticals,
• Biologics,
• Medicine;
• Clinical Research Organizations;
• Academic Research Centers;
• Regulatory Agencies